HALOZYME THERAPEUTICS, INC. (HALO)

Every figure this model derived for HALO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 12,371,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 342,363,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 933,024,000 AssetsCurrent 2026-06-30
current liabilities 344,439,000 LiabilitiesCurrent 2026-06-30
equity 143,543,000 StockholdersEquity 2026-06-30
interest expense 20,303,000 InterestExpenseNonoperating 2026-06-30
ocf 818,595,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,663,738,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 63,066,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up HALO on one particular measure came for.

RatioValue
cash operating margin32.87
current ratio2.71
current ratio reported2.71
deferred revenue growth85.91
dilution pct-4.27
ebit cagr17.42
ebit yoy-14.95
fcf margin48.46
growth cv0.4
interest cover23.1
net debt ebitda4.15
operating margin28.19
owner earnings margin44.67
revenue growth41.15
revenue growth per share47.45
roic17.21
rule of 4069.34
sbc pct revenue3.79

What to be careful about

What this model itself distrusts about HALO's figures. Written by the derivation as it ran, not added afterwards.